Development of a Recombinant Antibody for Gastrointestinal Cancers
Author Information
Author(s): Kim D-J, Chung J-H, Ryu Y-S, Rhim J-H, Kim C-W, Suh Y, Chung H-K
Primary Institution: Seoul National University College of Medicine
Hypothesis
Can a recombinant single-chain variable fragment (scFv) be produced that retains the binding capacity of the SC142 antibody to gastrointestinal cancer antigens?
Conclusion
The study successfully produced a recombinant scFv that can effectively bind to gastrointestinal cancer antigens, showing potential for diagnostic and therapeutic applications.
Supporting Evidence
- The SC142 scFv was shown to bind specifically to SC142-reactive antigens in gastrointestinal cancers.
- Immunohistochemical studies indicated that SC142 scFv was not detected in normal tissues but was present in 78% of gastric cancers and 87% of colon cancers.
- BIAcore analysis confirmed that SC142 scFv has a high affinity for its target antigen.
Takeaway
Scientists created a smaller version of an antibody that can find stomach and colon cancer cells better than the original antibody.
Methodology
The study involved producing scFv from hybridoma cells, followed by various analyses including ELISA and BIAcore binding studies.
Limitations
The study did not address the long-term stability and efficacy of the scFv in vivo.
Participant Demographics
The study involved human gastrointestinal cancer tissues, specifically gastric and colon cancers.
Statistical Information
P-Value
6.68×10−7
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website